US trial: NMT to change PFO/migraine goal
This article was originally published in Clinica
Executive Summary
Improving its chances of reaching the key goal in a pivotal US trial of its cardiac repair implant for treating migraine, NMT Medical has gained conditional approval from the FDA to adjust the primary endpoint of the study.